APL-2 + APL-2
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy
Conditions
Geographic Atrophy
Trial Timeline
Aug 31, 2018 → Jun 20, 2022
NCT ID
NCT03525600About APL-2 + APL-2
APL-2 + APL-2 is a phase 3 stage product being developed by Apellis Pharmaceuticals for Geographic Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT03525600. Target conditions include Geographic Atrophy.
What happened to similar drugs?
1 of 11 similar drugs in Geographic Atrophy were approved
Approved (1) Terminated (3) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03525600 | Phase 3 | Completed |
| NCT03525613 | Phase 3 | Completed |
Competing Products
20 competing products in Geographic Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 40 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 38 |
| avacincaptad pegol | Astellas Pharma | Approved | 50 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 33 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 40 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 39 |
| FWY003 + Placebo | Novartis | Phase 2 | 42 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 35 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 35 |
| Lampalizumab | Roche | Phase 3 | 32 |
| Lampalizumab | Roche | Phase 3 | 32 |
| Lampalizumab | Roche | Phase 3 | 32 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 36 |
| RO7303359 | Roche | Phase 1 | 29 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 39 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 36 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 24 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 41 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 24 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 34 |